PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩130 per share · Prices as of the 2026-10-02 close
Ercohs is expanding from its infant-food brand LUSOL into alternative foods, senior nutrition, and bio-healthcare, but net income turned negative in 2025 and operating losses have persisted in recent quarters.
2025 consolidated revenue was KRW 35.6bn, a slight decline, while operating margin fell sharply from 8.9% to 0.8%.
The company posted operating losses in four consecutive quarters from 2025Q3 through 2026Q2, with the loss widening through 2026.
2026Q2 revenue reached KRW 10.27bn, the highest of the past five quarters, but was accompanied by an operating loss.
Recurring convertible-bond derivative valuation losses have been disclosed, adding volatility to net income.
The company is expanding into bio-healthcare, including securing exclusive rights to the growth-support functional material 'WCO31'.
Founded in 2014, Ercohs is a food-tech company centered on its premium infant-food brand LUSOL, covering production and distribution of infant food products.
The company has expanded its lineup to include over 160 types of baby food, senior-friendly nutritional porridge, health-oriented bakery items, and health functional foods, leveraging technologies such as silk protein and TVP (textured vegetable protein) to enter the alternative-food segment.
As of the third quarter of 2025, infant food reportedly accounted for about 51.7% of revenue, with the remainder coming from convenience foods, alternative foods, and senior nutrition products.
During a period of poor pear harvests, the company faced rising raw-material costs for its pear-balloon flower juice product and struggled to pass through prices amid intensifying competition.
In early 2026, the company signed a joint business agreement with bio-material firm Wellrest, securing exclusive commercial rights to WCO31, a growth-support functional material for children, marking a strategic shift toward becoming a bio-healthcare company beyond simple food manufacturing.
On the distribution side, the company is diversifying channels between online platforms and offline stores. Ercohs listed on KOSDAQ on February 28, 2025 through a merger with Kiwoom No.6 SPAC.
Its competitive landscape spans both established domestic infant-food brands and newer entrants in the alternative-food and senior-nutrition markets.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩8.8B | ₩89,125,979 | 1.0% |
| 2025Q3 | ₩9B | -₩77,297,223 | −0.9% |
| 2025Q4 | ₩9.7B | -₩100M | −1.4% |
| 2026Q1 | ₩8.8B | -₩600M | −6.7% |
| 2026Q2 | ₩10.3B | -₩500M | −4.7% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2023 | ₩33B | ₩3.1B | ₩1.8B | 9.3% | 5.8% | 136.8% |
| 2024 | ₩36.5B | ₩3.2B | ₩900M | 8.9% | 2.4% | 124.3% |
| 2025 | ₩35.6B | ₩300M | -₩6.2B | 0.8% | −11.5% | 85.0% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-09-04
Annual revenue grew from KRW 33.01bn in 2023 to KRW 36.46bn in 2024, before slipping slightly to KRW 35.63bn in 2025. Operating profit remained stable at KRW 3.08bn (9.3% margin) in 2023 and KRW 3.24bn (8.9%) in 2024, but collapsed to KRW 270mn (0.8%) in 2025.
Net income attributable to owners stayed positive at KRW 1.82bn in 2023 and KRW 934mn in 2024, then swung to a loss of KRW 6.19bn in 2025.
On a quarterly basis, the company posted an operating profit of KRW 89mn on revenue of KRW 8.76bn in 2025Q2, but then recorded four consecutive quarters of operating losses: KRW -77mn in 2025Q3 (revenue KRW 8.99bn), KRW -140mn in 2025Q4 (revenue KRW 9.72bn), KRW -583mn in 2026Q1 (revenue KRW 8.77bn), and KRW -478mn in 2026Q2 (revenue KRW 10.27bn).
While revenue reached its highest level in five quarters in 2026Q2, signaling some top-line recovery, the loss actually widened in 2026 compared with 2025.
On the balance sheet, total equity rose steadily from KRW 31.21bn in 2023 to KRW 38.71bn in 2024 and KRW 53.89bn in 2025, bringing the debt ratio down from 136.8% (2023) to 124.3% (2024) and 85.0% (2025).
The 2025 net loss reflected a combination of factors including rising raw-material costs, higher SG&A from offline store expansion, and non-cash convertible-bond derivative valuation losses; the company disclosed roughly KRW 4.98bn in CB derivative valuation losses in August 2025, followed by an additional derivative loss disclosure in February 2026. Operating cash flow also weakened sharply, falling from KRW 5.13bn in 2024 to KRW 210mn in 2025.
The domestic infant-food market faces structural demand pressure from Korea's low birth rate, though premiumization and functional-ingredient trends leave room for brand differentiation. Ercohs is reported to have previously gained market share after quality issues at competitor products.
The alternative food and plant-based meat market is drawing attention globally as a growth area, though differing national approval procedures and safety standards for ingredients remain a key challenge for overseas expansion.
The senior-nutrition food market is viewed as having medium-to-long-term growth potential given Korea's aging population, drawing interest from multiple food companies including Ercohs.
In functional-ingredient markets such as growth-support materials, individually recognized ingredient registration and clinical data requirements act as entry barriers, which Ercohs is attempting to navigate by securing exclusive rights to WCO31.
Overall, the industry combines a maturing core market (infant food) with early-stage growth businesses (alternative foods, functional materials, healthcare), and the company appears to be in the early stages of diversifying its business mix toward these newer segments.
The company has stated it completed facility investment for new-product production lines, including one extracting active ingredients from scallion (chongbaek) and Schisandra berries, during the first half of 2026, with production and sales planned to begin in the second half.
Regarding the growth-support material WCO31, the company said it planned to complete individually recognized ingredient registration with the Ministry of Food and Drug Safety within the first half of 2026, with raw-material and finished-product mass production to start in the second half.
On overseas expansion, the company said it was in discussions with partners including a China-listed company as well as counterparts in Vietnam, Taiwan, and Singapore, though no specific contracts have been confirmed yet.
On financing, the company was reported in January 2026 to be pursuing a KRW 13.5bn convertible-bond issuance aimed at expanding its product lineup beyond infant food into a full life-cycle portfolio.
Kiwoom Securities, in a report dated December 22, 2025, assessed that the company was building a mid- to long-term growth foundation through channel and product diversification.
The same brokerage had earlier, in a June 2025 report, expected second-half profitability improvement driven by a two-track pricing strategy and expanded dessert-category sales, though actual quarterly results from the second half of 2025 through the first half of 2026 instead showed continued operating losses, diverging from that earlier expectation.
Since net income turned negative in 2025 and has remained in a loss position over the most recent four quarters, conventional earnings-based valuation metrics are difficult to apply in the usual way.
The price-to-net-asset relationship has been influenced by steady equity growth since listing, and the decline in the debt ratio can be read as a positive signal for the balance sheet.
While the company has a history of cash dividends, the sustainability of future dividend policy warrants monitoring given the recent net loss.
With earnings currently in loss territory, market pricing appears to reflect expectations tied to the visibility of new-business performance (alternative foods, bio-healthcare), a dynamic that depends heavily on how market participants assess the pace of any earnings recovery.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-09-04
Securing exclusive rights to WCO31 has enabled expansion into functional materials such as growth support and blood-glucose management, potentially easing the company's reliance on infant food.
Mass production of related raw materials and finished products is planned to begin in the second half of 2026, making the emergence of new revenue streams a key point to watch. Discussions with overseas partners are also reportedly underway.
2026Q2 revenue of KRW 10.27bn was the highest in the past five quarters, suggesting the top line may be recovering from a low point. Channel and product diversification appears to be contributing to the revenue expansion.
Total equity rose steadily from KRW 31.2bn in 2023 to KRW 53.9bn in 2025, while the debt ratio fell from 136.8% to 85.0%. This can be viewed as a positive signal for financial stability despite the swing to a net loss.
Operating losses persisted from 2025Q3 through 2026Q2, with the loss actually widening in 2026. Even in 2026Q2, when revenue grew, the company still posted an operating loss of KRW -478mn, indicating cost-structure improvement has not yet clearly materialized.
Convertible-bond-related derivative valuation losses were disclosed repeatedly in August 2025 and February 2026. These non-cash losses add volatility to reported net income, and similar losses could recur if the planned KRW 13.5bn convertible bond issuance proceeds.
Rising raw-material costs from poor pear harvests, combined with difficulty passing through prices amid expanding competing products, have been cited as key causes of past earnings weakness. Higher SG&A from offline store expansion has also weighed on profitability.
Convertible-bond derivative valuation losses may recur repeatedly depending on stock price movements, potentially sustaining volatility in reported net income. Additional convertible bond issuance could bring potential equity dilution and repeated valuation losses.
While mass production and sales plans for new products (growth-support materials, alternative foods) are scheduled for the second half, the actual timing and scale of their revenue contribution remain unverified. It is also uncertain whether overseas partnership discussions will result in concrete contracts.
Structural demand pressure on the infant-food market from Korea's low birth rate continues, while the alternative-food and functional-material markets carry ongoing regulatory-compliance burdens across different countries. Raw-material (agricultural commodity) price volatility can also continue to affect profitability.
The 2026Q3 earnings disclosure should be checked to see whether operating losses persist and whether the recent revenue recovery continues.
Whether actual mass production and sales of the growth-support material WCO31 and new products (scallion/Schisandra extracts) begin as planned, and their contribution to revenue, should be monitored.
Whether the planned KRW 13.5bn convertible bond issuance is actually completed, on what terms, and the resulting potential for equity dilution or renewed derivative valuation losses should be checked.
Whether additional convertible-bond derivative transaction loss disclosures occur, and whether conversion of the bonds into equity progresses (with its capital-strengthening effect), should be monitored.
Ercohs, built on its infant-food brand LUSOL, is in the process of expanding into alternative foods, senior nutrition, and bio-healthcare, with 2026Q2 revenue reaching its highest level in five quarters, suggesting some top-line recovery.
However, since net income turned negative in 2025, the company has posted operating losses in four consecutive quarters from 2025Q3 through 2026Q2, with the loss actually widening in 2026. This appears to reflect a combination of rising costs, higher SG&A, and convertible-bond-related derivative valuation losses.
On the other hand, total equity has grown steadily and the debt ratio has declined, pointing to a more positive trend in financial stability.
New-business initiatives, including exclusive rights to the growth-support material WCO31 and discussions with overseas partners, are underway, though the timing and scale of their actual revenue contribution remain unconfirmed.
Key items to watch going forward include the start of new-product mass production and sales, progress on the planned convertible bond issuance, and whether quarterly profit and loss trends improve.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.